Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Hampel, Paul J., Ding, Wei, Call, Timothy G., Rabe, Kari G., Kenderian, Saad S., Witzig, Thomas E., Muchtar, Eli, Leis, Jose F., Chanan-Khan, Asher A., Koehler, Amber B., Fonder, Amie L., Schwager, Susan M., Slager, Susan L., Shanafelt, Tait D., Kay, Neil E., Parikh, Sameer A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6813846/
https://ncbi.nlm.nih.gov/pubmed/31014142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1602268
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados